BioCryst rallies on gout study; indices diverge – MarketWatch

By Dr. Matthew Watson


HealthNewsDigest.com
BioCryst rallies on gout study; indices diverge
MarketWatch
The NYSE Arca Pharmaceutical Index (INDEX:DRG) was down marginally at 293.68 while the NYSE Arca Biotechnology Index (INDEX:BTK) rose 0.6% to 1178.34.
BioCryst Reports Positive Results from Part One of Its Phase 2a Study of ...MarketWatch (press release)
BioCryst says gout drug shows positive resultsReuters

all 40 news articles »



categoriaUncategorized commentoComments Off on BioCryst rallies on gout study; indices diverge – MarketWatch | dataApril 29th, 2010

About...

This author published 5432 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024